ASX - By Stock
|
CYP |
Re:
Ann: Successful Completion of Planned DSMB Review of DFU Trial
|
|
Zenox
|
48 |
12K |
3 |
12/10/22 |
12/10/22 |
ASX - By Stock
|
48
|
12K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
2 |
12/10/22 |
12/10/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Successful Completion of Planned DSMB Review of DFU Trial
|
|
Zenox
|
48 |
12K |
1 |
12/10/22 |
12/10/22 |
ASX - By Stock
|
48
|
12K
|
1
|
|
ASX - By Stock
|
ILA |
Re:
Ann: ISLA-101 Phase 2a clinical trial update
|
|
Zenox
|
43 |
15K |
4 |
11/10/22 |
11/10/22 |
ASX - By Stock
|
43
|
15K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Potential Financial Implications of Yesterday's Results
|
|
Zenox
|
97 |
44K |
8 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
97
|
44K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Potential Financial Implications of Yesterday's Results
|
|
Zenox
|
97 |
44K |
0 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
97
|
44K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Competition???
|
|
Zenox
|
61 |
25K |
3 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
61
|
25K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Competition???
|
|
Zenox
|
61 |
25K |
2 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
61
|
25K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Competition???
|
|
Zenox
|
61 |
25K |
5 |
10/10/22 |
10/10/22 |
ASX - By Stock
|
61
|
25K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Competition???
|
|
Zenox
|
61 |
25K |
12 |
07/10/22 |
07/10/22 |
ASX - By Stock
|
61
|
25K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Competition???
|
|
Zenox
|
61 |
25K |
7 |
07/10/22 |
07/10/22 |
ASX - By Stock
|
61
|
25K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
Zenox
|
115 |
63K |
9 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
115
|
63K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
Zenox
|
115 |
63K |
20 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
63K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
Zenox
|
115 |
63K |
2 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
63K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
Zenox
|
115 |
63K |
11 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
63K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
|
Zenox
|
115 |
63K |
27 |
04/10/22 |
04/10/22 |
ASX - By Stock
|
115
|
63K
|
27
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Zenox
|
115 |
58K |
20 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
115
|
58K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Zenox
|
115 |
58K |
14 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
115
|
58K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Trading Halt
|
|
Zenox
|
115 |
58K |
7 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
115
|
58K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
5 |
29/09/22 |
29/09/22 |
ASX - By Stock
|
104
|
40K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
6 |
28/09/22 |
28/09/22 |
ASX - By Stock
|
104
|
40K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
18 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
18
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
11 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
21 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
11 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful MPSVI Safety Review and PARA OA 008 Update
|
|
Zenox
|
104 |
40K |
10 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
104
|
40K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Zenox
|
670 |
255K |
3 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
670
|
255K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Zenox
|
670 |
255K |
9 |
22/09/22 |
22/09/22 |
ASX - By Stock
|
670
|
255K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
10 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
Zenox
|
109 |
39K |
4 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
109
|
39K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
Zenox
|
109 |
39K |
1 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
109
|
39K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
Zenox
|
109 |
39K |
14 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
109
|
39K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Successful Completion of Entitlement Offer
|
|
Zenox
|
109 |
39K |
5 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
109
|
39K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
1 |
19/09/22 |
19/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
NSB |
Re:
Ann: HREC decision to not approve Phase I Clinical Trial
|
|
Zenox
|
96 |
38K |
2 |
10/09/22 |
10/09/22 |
ASX - By Stock
|
96
|
38K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
4 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
4
|
|
ASX - By Stock
|
NSB |
Re:
Ann: HREC decision to not approve Phase I Clinical Trial
|
|
Zenox
|
96 |
38K |
3 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
96
|
38K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
2 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
1 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
NSB |
Re:
Ann: HREC decision to not approve Phase I Clinical Trial
|
|
Zenox
|
96 |
38K |
7 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
96
|
38K
|
7
|
|
ASX - By Stock
|
NSB |
Re:
Ann: HREC decision to not approve Phase I Clinical Trial
|
|
Zenox
|
96 |
38K |
15 |
08/09/22 |
08/09/22 |
ASX - By Stock
|
96
|
38K
|
15
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
5 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
0 |
26/08/22 |
26/08/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
Zenox
|
87 |
35K |
4 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
87
|
35K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
Zenox
|
84 |
30K |
2 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
84
|
30K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
Zenox
|
84 |
30K |
7 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
84
|
30K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
2b or NOT to be
|
|
Zenox
|
84 |
30K |
5 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
84
|
30K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Launches $66M Capital Raising
|
|
Zenox
|
132 |
56K |
13 |
16/08/22 |
16/08/22 |
ASX - By Stock
|
132
|
56K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
Zenox
|
87 |
35K |
16 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
87
|
35K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Investor Presentation - $66m Capital Raise
|
|
Zenox
|
87 |
35K |
10 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
87
|
35K
|
10
|
|